Breaking News

Tweet TWEET

Before the Bell Scans of Mylan, Forest Laboratories, Avanir Pharma, Akorn, and Medicines Co.

Before the Bell Scans of Mylan, Forest Laboratories, Avanir Pharma, Akorn, and                                 Medicines Co.  PR Newswire  LONDON, March 8, 2013  LONDON, March 8, 2013 /PRNewswire/ --  The U.S. Supreme Court last year upheld President Obama's Affordable Care Act (ACA). The ACA is the biggest overhaul of the healthcare industry in decades. While critics say that ACA will have a negative impact on the healthcare industry, supporters of the reform believe that the increase in the amount of insured individuals will ultimately benefit the industry. Apart from ACA, another major trend that is having an impact on drug makers such as Mylan Inc. (NASDAQ: MYL), Forest Laboratories Inc. (NYSE: FRX), Avanir Pharmaceuticals Inc. (NASDAQ: AVNR), Akorn Inc. (NASDAQ: AKRX) and The Medicines Company (NASDAQ: MDCO) is the expiration of patents on several blockbuster drugs. On Thursday, drug makers ended on a mixed note even as the broad market rallied. StockCall has taken an interest in these companies and you can now sign up to download the free technical research on MYL, FRX, AVNR, AKRX, and MDCO at  http://www.stockcall.com/registration   Shares of Mylan Inc. slipped in trading on Thursday. However, losses were limited. The stock slipped after hitting a 52-week high of $31 in Thursday's trading session. Mylan's shares closed 0.36% lower at $30.79 on above average volume of 5.74 million. Shares of MYL have had an excellent run so far this year, gaining more than 12%, compared to a gain of more than 8.20% for the S&P 500. The drug maker company's shares have recently broken through $29 resistance level, which is a bullish signal. The stock is also trading above its 50-day and 200-day moving averages, which further confirms the bullish trend. Sign up today to read the free research report on MYL at  http://www.StockCall.com/MYL030813.pdf   Forest Laboratories Inc.'s shares rose in Thursday's trading session; however, the gains were limited. The stock closed 0.24% higher at $37.38 on volume of 1.35 million. The company's shares are currently trading close to their 52-week high of $38.45. Year-to-date, the stock has underperformed the broad market, gaining nearly 6%, compared to a gain of more than 8.20% for the S&P 500. Forest Laboratories shares are currently trading above their 50-day and 200-day moving averages, which is a bullish signal. The bullish trend is further confirmed by the stock's MACD chart. Register to download the free technical analysis on FRX at  http://www.StockCall.com/FRX030813.pdf   Shares of Avanir Pharmaceuticals Inc. rose more than 1% in Thursday's trading session, extending its gains for the week. The stock closed 1.01% higher at $2.99 on Thursday and has now gained more than 7.50% in the last three sessions. Year-to-date, the stock has now gained more than 14.20%. Avanir Pharma's shares have recently broken through $2.80 resistance level, which is a bullish signal. The stock has also crossed its 50-day moving average, which further confirms the bullish trend. The stock's MACD has just crossed above the signal line. Free report on AVNR can be accessed by registering at  http://www.StockCall.com/AVNR030813.pdf   Shares of Akorn Inc. ended marginally higher in Thursday's trading session. The stock closed 0.36% higher at $13.87 on volume of 234,270. Year-to-date, the stock has gained more than 3.80%. Akorn's shares are currently facing resistance at around $14. Register with StockCall and download the research on AKRX for free at  http://www.StockCall.com/AKRX030813.pdf   Shares of The Medicines Company fell sharply in Thursday's trading session. The stock closed 1.64% lower at $31.70 on above average volume of 797,089. Year-to-date, the stock has gained more than 32%, outperforming the broad market. Read the full free research on MDCO by signing up to StockCall at  http://www.StockCall.com/MDCO030813.pdf   About StockCall.com  StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at  http://www.stockcall.com  SOURCE StockCall.com  Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact Number: +1-(646)-396-9857 (9:00 am EST - 01:30 pm EST)  
Press spacebar to pause and continue. Press esc to stop.